Savient Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 72   

Articles published

SVNTQ 0.0019
price chart
Bridgewater-based Savient Pharmaceuticals OKd for Chapter 11 plan
Savient Pharmaceuticals Inc., a developer of a treatment for gout before its business was sold, got approval of a liquidating Chapter 11 plan, with U.S.
Savient Pharmaceuticals Files for Bankruptcy
Oct. 14 (Bloomberg) -- Savient Pharmaceuticals Inc., the developer of a treatment for gout, sought bankruptcy protection and court approval to sell its assets to a US WorldMeds LLC unit for $55 million, the company said.
Savient Pharmaceuticals files for Chapter 11 bankruptcy  Reuters
Savient Pharmaceuticals Commences Voluntary Chapter 11 Proceeding; Seeks ...  PR Newswire (press release)
Related articles »  
Savient Pharmaceuticals, Inc. (SVNT): Are Hedge Funds Right About This Stock?
When looking at the hedgies we track, William Leland Edwards's Palo Alto Investors had the most valuable position in Savient Pharmaceuticals, Inc. (NASDAQ:SVNT), worth close to $11.8 million, accounting for 1.4% of its total 13F portfolio. Coming in ...
Related articles »  
Savient Pharmaceuticals: Value Play Or Value Trap?
Savient Pharmaceuticals, Inc. (SVNT), based in East Brunswick, NJ is a biotechnology company engaged in the commercialization of Krystexxa (first and only in its class), for refractory chronic gout (RCG), an indication for which SVNT has obtained ...
Savient Pharmaceuticals Announces Formation of Office of the President
BRIDGEWATER, N.J., June 20, 2013 /PRNewswire via COMTEX/ -- Savient Pharmaceuticals, Inc. SVNT announced today that it has formed an Office of the President, consisting of Richard Crowley, who will serve as Co-President and Chief Operating Officer, ...
Related articles »  
Savient Pharmaceuticals: Is Anything Left?
This is hardly enough to sustain the company, and it took a loss of $28.0 million for that quarter. With SVNT's current cash cushion of $96.3 million, it is clear that Savient will have to turn something around, and fast. Its prescription rates for ...
Savient Pharmaceuticals: Sluggish Launch Of Krystexxa Presents Buying ...
Savient is an emerging biotechnology company that is in the early stages of launching its first product, Krystexxa (pegloticase) for chronic refractory gout patients.
Related articles »  
Trying to Get a Handle on Savient Pharmaceuticals' Valuation
The shares of Savient plunged on this news. They fell further Tuesday as short sellers continued to try to push the stock down.
Related articles »  
Savient Pharma Unveils Ch. 11 Plan
Law360, New York (February 10, 2014, 7:01 PM ET) -- Drug developer Savient Pharmaceuticals Inc. unveiled its Chapter 11 plans in Delaware bankruptcy court Monday, calling for the liquidation of its U.S.
Related articles »  
Savient Pharmaceuticals: Thoughts On The Chronic Refractory Gout Market
Savient has spent a great deal of time trying to size the patient population and has come up with some interesting data. The company starts with the NHANES survey performed by the Center for Disease Control that did a detailed study of the entire gout ...
Related articles »